Article thumbnail

Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging

By A.H. Maurer, P. Elsinga, S. Fanti, B. Nguyen, W.J.G. Oyen and W.A. Weber

Abstract

Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. (99m)Tc-etarfolatide, a (99m)Tc-labeled folate conjugate, is in late-phase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy

Year: 2014
DOI identifier: 10.2967/jnumed.113.133074
OAI identifier:
Provided by: NARCIS
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.loc.gov/mods/v3 (external link)
  • http://hdl.handle.net/2066/138... (external link)
  • http://hdl.handle.net/2066/138... (external link)
  • https://repository.ubn.ru.nl/d... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.